Pediatric Hematology/Oncology Seminar and Workshops Announced

Publication
Article
OncologyONCOLOGY Vol 12 No 10
Volume 12
Issue 10

Advances in Pediatric Hematology/Oncology will be held November 19 through 21, 1998, at the Hilton Clearwater Beach Resort, Florida (formerly the DoubleTree). Topics presented by nationally renowned speakers include:

Advances in Pediatric Hematology/Oncology will be held November 19 through 21, 1998, at the Hilton Clearwater Beach Resort, Florida (formerly the DoubleTree). Topics presented by nationally renowned speakers include:

  • Transplantation

  • Pain management

  • Sickle cell disease

  • Immune tolerance/inhibitors

  • HIV-related malignancy

  • Pathology, new cancer agents

  • Supportive care

Representatives of various organizations will display the latest in supplies, products, and services.

Early registration fees are $130 and $50 for full-time students/residents (with accompanying letter from a faculty advisor). Please inquire about late registration fees and single-day rates.

Workshops will be held Saturday, November 21, on the topics of medical Spanish (prerequisite, knowledge of conversational Spanish) and alternative therapies for pediatric patients.

For registration forms or sponsorship opportunities please contact: The Florida Association of Pediatric Tumor Programs, P. O. Box 17757, Tampa, FL 33682-7757; phone: (813) 632-1309; e-mail: FAPTP@moffit.usf.edu.

Recent Videos
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content